| The behavioral pharmacology of hallucinogens WE Fantegrossi, KS Murnane, CJ Reissig Biochemical pharmacology 75 (1), 17-33, 2008 | 302 | 2008 |
| Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ9-THC: mechanism underlying greater toxicity? WE Fantegrossi, JH Moran, A Radominska-Pandya, PL Prather Life sciences 97 (1), 45-54, 2014 | 287 | 2014 |
| Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity LK Brents, EE Reichard, SM Zimmerman, JH Moran, WE Fantegrossi, ... PloS one 6 (7), e21917, 2011 | 265 | 2011 |
| Baths salts, spice, and related designer drugs: the science behind the headlines MH Baumann, E Solis, LR Watterson, JA Marusich, WE Fantegrossi, ... Journal of neuroscience 34 (46), 15150-15158, 2014 | 204 | 2014 |
| Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine CL Moran, VH Le, KC Chimalakonda, AL Smedley, FD Lackey, SN Owen, ... Analytical chemistry 83 (11), 4228-4236, 2011 | 202 | 2011 |
| Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to … LK Brents, A Gallus-Zawada, A Radominska-Pandya, T Vasiljevik, ... Biochemical pharmacology 83 (7), 952-961, 2012 | 197 | 2012 |
| 3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") and its stereoisomers as reinforcers in rhesus monkeys: serotonergic involvement WE Fantegrossi, T Ullrich, KC Rice, JH Woods, G Winger Psychopharmacology 161 (4), 356-364, 2002 | 175 | 2002 |
| In vivo effects of abused ‘bath salt’constituent 3, 4-methylenedioxypyrovalerone (MDPV) in mice: drug discrimination, thermoregulation, and locomotor activity WE Fantegrossi, BM Gannon, SM Zimmerman, KC Rice Neuropsychopharmacology 38 (4), 563-573, 2013 | 162 | 2013 |
| MDMA use and neurocognition: a meta-analytic review AD Kalechstein, R De La Garza, JJ Mahoney, WE Fantegrossi, TF Newton Psychopharmacology 189, 531-537, 2007 | 161 | 2007 |
| Pharmacological characterization of the effects of 3, 4-methylenedioxymethamphetamine (" ecstasy") and its enantiomers on lethality, core temperature, and locomotor activity in … WE Fantegrossi, T Godlewski, RL Karabenick, JM Stephens, T Ullrich, ... Psychopharmacology 166, 202-211, 2003 | 152 | 2003 |
| Pharmacological characterization of the effects of 3, 4-methylenedioxymethamphetamine (" ecstasy") and its enantiomers on lethality, core temperature, and locomotor activity in … WE Fantegrossi, T Godlewski, RL Karabenick, JM Stephens, T Ullrich, ... Psychopharmacology 166, 202-211, 2003 | 152 | 2003 |
| Pharmacological and toxicological effects of synthetic cannabinoids and their metabolites S Tai, WE Fantegrossi Neuropharmacology of New Psychoactive Substances (NPS) The Science Behind …, 2017 | 137 | 2017 |
| The value of nonhuman primates in drug abuse research. EM Weerts, WE Fantegrossi, AK Goodwin Experimental and clinical psychopharmacology 15 (4), 309, 2007 | 130 | 2007 |
| Behavioral and neurochemical consequences of long-term intravenous self-administration of MDMA and its enantiomers by rhesus monkeys WE Fantegrossi, WL Woolverton, M Kilbourn, P Sherman, J Yuan, ... Neuropsychopharmacology 29 (7), 1270-1281, 2004 | 128 | 2004 |
| Forensic investigation of K2, Spice, and “bath salt” commercial preparations: a three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and … KA Seely, AL Patton, CL Moran, ML Womack, PL Prather, WE Fantegrossi, ... Forensic science international 233 (1-3), 416-422, 2013 | 126 | 2013 |
| Synthetic pot: not your grandfather’s marijuana BM Ford, S Tai, WE Fantegrossi, PL Prather Trends in pharmacological sciences 38 (3), 257-276, 2017 | 125 | 2017 |
| Synthetic cannabinoids: pharmacology, behavioral effects, and abuse potential S Tai, WE Fantegrossi Current addiction reports 1, 129-136, 2014 | 125 | 2014 |
| Transient reinforcing effects of phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys WE Fantegrossi, JH Woods, G Winger Behavioural pharmacology 15 (2), 149-157, 2004 | 113 | 2004 |
| In vivo effects of synthetic cannabinoids JWH-018 and JWH-073 and phytocannabinoid Δ9-THC in mice: inhalation versus intraperitoneal injection R Marshell, T Kearney-Ramos, LK Brents, WS Hyatt, S Tai, PL Prather, ... Pharmacology Biochemistry and Behavior 124, 40-47, 2014 | 111 | 2014 |
| AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies KA Seely, LK Brents, LN Franks, M Rajasekaran, SM Zimmerman, ... Neuropharmacology 63 (5), 905-915, 2012 | 111 | 2012 |
Anna Radominska-Pandya, Ph.D.Professor, University of Arkansas for Medical SciencesVerified email at uams.edu
